cd134-epipen-hearing

CD134: The EpiPen Hearing

Epinephrine injectors are life saving devices for people with food allergies and one company – Mylan Inc. – produces almost all of them. In this episode, listen to the highlights from a House Oversight and Government Reform Committee grilling of Mylan CEO Heather Bresch, and judge her justification for raising the EpiPen's price over 600% since EpiPen's competition was eliminated.


Please support Congressional Dish:

  • Click here to contribute with PayPal or Bitcoin

  • Mail Contributions to: 2244 Oak Grove Rd, P.O. Box 30507, Walnut Creek, CA 94598

  • Click here to shop on Amazon – Congressional Dish will receive a referral commission.

Thank you for supporting truly independent media!


Sound Clip Sources

Hearing: EpiPen Price Increases (Watch on C-SPAN)

House Oversight and Government Reform Committee, September 21, 2016.

Witnesses

Clip Timestamps

(In order of appearance in episode)

  • 51:16Doug Throckmorton: Available epinephrine injectors

  • 49:55Rep. John Mica (FL) and Doug Throckmorton: FDA won't discuss generic applications

  • 0:35Chairman Jason Chaffetz (UT) – Introduction

  • 9:25Elijah Cummings (MD): Mylan's actions that Congress is investigating

  • 12:20Elijah Cummings: List of EpiPen price increases

  • 4:10Jason Chaffetz: Executive compensation

  • 16:55Elijah Cummings: Martin Shkreli called Congress "imbeciles"

  • 24:10Heather Bresch: Introduction

  • 28:16Heather Bresch: Mylan's profits from each EpiPen

  • 47:43Rep. Elijah Cummings (MD) & Heather Bresch: Mylan did not give Congress requested documents

  • 55:10Rep. Eleanor Holmes Norton & Heather Bresch: Will Mylan reduce the price of EpiPens?

  • 1:23:26Rep. Scott DesJarlais (TN) & Heather Bresch: How long were the price increases going to continue?

  • 1:32:10Rep. Gerald Connolly (VA) & Heather Bresch: Mylan's EpiPen is 94% of the epinephrine injector market.

  • 1:56:55Rep. Stacey Plaskett (VI) & Heather Bresch: Why are customers paying so much for EpiPens?

  • 2:01:04Rep. Mark Meadows (NC) & Heather Bresch: Everyone pays a different price in this system

  • 2:51:15Rep. Bonnie Watson Coleman (NJ) & Heather Bresch: Mylan moved their headquarters to the Netherlands to pay less in U.S. taxes.

  • 2:37:15Rep. Peter Welch & Heather Bresch: EpiPens cost much less in the Netherlands

  • 1:03:15Rep. John Duncan (TN): Drug companies have manipulated the market.

  • 1:44:25Tammy Duckworth (IL) & Heather Bresch: Mylan prohibited schools from buying from competitors

  • 36:45Rep. Jason Chaffetz (UT) & Heather Bresch: Heather Bresch's explanation for why her mother used her position to get schools to buy EpiPens from Mylan

  • 1:11:40Rep. Tim Walberg (MI) & Heather Bresch: Mylans plan would shift costs of EpiPens to government

  • 1:21:16Rep. Stephen Lynch (MA) & Heather Bresch: Veterans Administration is able to negotiate it's drug prices, which makes them lower

  • 53:35Rep. John Mica (FL) & Heather Bresch: Executive compensation at Mylan

  • 59:19Rep. Eleanor Holmes Norton (DC) & Heather Bresch: What does Heather Bresch do to earn $18 million per year?

  • 2:48:55Rep. Bonnie Watson Coleman (NJ) & Heather Bresch: Heather Bresch often uses a company private jet

  • 2:13:50Rep. Mick Mulvaney (SC) & Heather Bresch: Mylan is getting what it deserves

  • 3:08:08Rep. Glenn Grothman (WI) & Heather Bresch: Does Heather Bresch feel guilty?

  • 3:39:40Rep. Jason Chaffetz & Heather Bresch: The numbers don't add up.

  • 3:43:30Rep. Elijah Cummings (MD) Closing statement


Additional Reading


Additional Information


Music Presented in This Episode


Cover Art

Design by Only Child Imaginations

OCI

How you can help the show...

Congressional Dish Voicemail Line: (339) 707-0307